¼¼°èÀÇ In Vivo CRO ½ÃÀå - ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : ¸ðµ¨ À¯Çüº°, ¸ð´Þ¸®Æ¼º°, ÀûÀÀÁõº°, GLP À¯Çüº°, Áö¿ªº°, ºÎ¹® ¿¹Ãø(2025-2030³â)
In Vivo CRO Market Size, Share & Trends Analysis Report By Model Type (Rodent Based, Non-Rodent Based), By Modality (Small Molecule, Large Molecule), By Indication, By GLP Type, By Region, And Segment Forecasts, 2025 - 2030
»óǰÄÚµå : 1632628
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2024³â 12¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 150 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,407,000
Unprintable PDF & Excel (Single User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» 1Àθ¸ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,950 £Ü 9,820,000
Printable PDF & Excel (5-User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ ºÎ¼­¿¡¼­ ÃÖ´ë 5¸í±îÁö »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,646,000
Printable PDF & Excel (Enterprise License) help
º¸°í¼­ ±¸¸Å ±â¾÷ ¹× ±× ÀÚȸ»ç, °ü°è»ç°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀ̸ç, PDF ¹× ¿¢¼¿ ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

In Vivo CRO ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ :

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¼¼°è In Vivo CRO ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 79¾ï 6,000¸¸ ´Þ·¯¿¡ À̸£¸ç, 2025³âºÎÅÍ 2030³â±îÁöÀÇ CAGRÀº 8.13%·Î È®´ëµÉ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

½ÅÈï±¹ÀÇ ÀǾàǰ ½ÃÀå ¼ºÀå, ¼ö¸¹Àº In Vivo ¼¼Æ÷ Ä¡·á¿¡ ´ëÇÑ ¿Õ¼ºÇÑ ¼ö¿ä, Àç·á °úÇÐÀÇ ±Þ¼ÓÇÑ Áøº¸, ¾à¹°°ú ÀåÄ¡ÀÇ Á¶ÇÕÀÇ º¹À⼺ µîÀÌ ÀÌ Áö¿ªÀÇ ¼­ºñ½º ¼ö¿ä·Î À̾îÁö°í ÀÖ½À´Ï´Ù., In Vivo ÀüÀÓ»ó ¹× ÀÓ»ó ¿¬±¸ Áõ°¡, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ½ÃÀå ÁøÃâ±â¾÷¿¡ ÀÇÇÑ ¼­ºñ½ºÀÇ È®´ë, ´Ù¾çÇÑ Áúº´ÀÇ ºÎ´ãÀÌ ½ÃÀå ¼öÀÍ¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.¿¡¼­ ¾Æ¿ô¼Ò½Ì Áõ°¡´Â In Vivo CRO ½ÃÀåÀÇ ¼ºÀåÀ» Áö¿øÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù.

¸¶Âù°¡Áö·Î ½ÅÈï±¹¿¡ ´ëÇÑ ÀǾàǰÀÇ ÇØ¿Ü°¡ Áõ°¡Çϰí ÀÖ´Â °Íµµ ÀÌ ½ÃÀå¿¡ ¸·´ëÇÑ ¼ö¿ä¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. ¼±Áø±¹¿¡¼­ÀÇ ¿¹»êÀÇ Á¶»ç, °¡°Ý¾Ð·Â, »óȯÁ¦µµÀÇ º¯°æÀº Àεµ³ª Áß±¹ µî ½ÅÈï ±¹°¡¿¡¼­ÀÇ ÀǾàǰ ÈÄ¿øÀÚ¿¡ ÀÇÇÑ ºñ¿ë¾ïÁ¦Ã¥ÀÇ Ã¤¿ëÀ» Áõ°¡½Ãų °ÍÀ¸·Î ¿¹»óµÇ´Â ÁÖ¿ä ¿äÀÎÀÇ ÀϺÎÀÔ´Ï´Ù. ½ÅÈï ±¹°¡¿¡¼­´Â ÀüÀÓ»ó In Vivo ¼­ºñ½º µîÀÇ °³¹ß ¼­ºñ½º¸¦ °è¾à ¼­ºñ½º Á¦°ø¾÷ü¿¡°Ô ¾Æ¿ô¼Ò½ÌÇÔÀ¸·Î½á ǰÁúº¸Áõ¡¤¾à»ç ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô¾ÆÁö°í In Vivo ¾Æ¿ô¼Ò½Ì ¼­ºñ½º ¼ö¿ä Áõ°¡¿¡ ±â¿©ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. FDA ½ÂÀÎÀ» À§ÇÑ ¾ö°ÝÇÑ ÇÁ·Î¼¼½º¿Í EU Áö¿ªÀÇ ±ÔÁ¦ º¯°æÀº À¯·´¿¡¼­ ½ÂÀÎ ÇÁ·Î¼¼½º¸¦ º¹ÀâÇÏ°Ô ¸¸µé °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À̵éÀº Á¦¾à ȸ»çÀÇ ½ÅÈï ±¹°¡·Î ÇØ¿Ü¿¡ ±â¿©ÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù.

COVID-19 ÆÒµ¥¹ÍÀº ´çÃÊ ÀÓ»ó½ÃÇè ¾÷°è¿¡ ¾Ç¿µÇâÀ» ÁÖ¾úÁö¸¸, In Vivo CRO ½ÃÀåµµ ¸¶Âù°¡Áö¿´½À´Ï´Ù. COVID-19¿¡ ´ëÀÀÇÏ¿© ¹ÙÀÌ¿ÀÀǾàǰ¾÷°è°¡ ¹é½Å°ú Ä¡·á¹ýÀÇ °³¹ß¿¡ ÁßÁ¡À» ¿Å±ä °á°ú, ´Ù¸¥ ÁúȯÀÇ ÀÓ»ó½ÃÇèÀ» È¥¶õ½Ãų °¡´É¼ºÀ̶ó´Â ¿¹±âÄ¡ ¾ÊÀº °á°ú¸¦ ÃÊ·¡Çß½À´Ï´Ù. ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á ¾÷°è¿¡¼­ »ç¾÷À» Àü°³ÇÏ´Â ±â¾÷ÀÌ Á÷¸éÇÏ´Â Áß¿äÇÑ ¹®Á¦ Áß Çϳª´Â ÇÊ¿äÇÑ ÀÓ»ó½ÃÇè ½Ç½Ã ½Ã¼³¿¡¼­ ȯÀÚ¿¡°Ô Ä¡·áÁ¦¸¦ Àû½Ã¿¡ Á¦°øÇÒ ¼ö ¾ø´Ù´Â °ÍÀÔ´Ï´Ù. °Ô´Ù°¡, ¼¼Æ÷ ±â¹Ý Ä¡·áÁ¦ÀÇ Åõ¿©´Â À¯Çà ÈÄ¿¡ ¸î °¡Áö °úÁ¦¸¦ ¾ß±âÇÕ´Ï´Ù. º´¿øÀº SARS-CoV-2ÀÇ Æ®·£½º¹Ì¼Ç, ƯÈ÷ ¾àÇÑ ÀÔÀåÀÇ »ç¶÷¿¡ ´ëÇÑ °¨¿°À» ¿ì·ÁÇϰí, ¼¼Æ÷ Ä¡·á ¼­ºñ½ºÀÇ Á¦°øÀ» ¸Á¼³À̰í ÀÖ½À´Ï´Ù. ȯÀÚ´Â Àá±Ý ¹× ¿©Çà ±ÝÁö¸¦ À§ÇØ ¼¼Æ÷ Ä¡·á ¼¾Å͸¦ ¹æ¹® ÇÒ ¼ö ¾ø½À´Ï´Ù.

¶ÇÇÑ ÁÖ¿ä ÁøÃâ±â¾÷Àº ¼¼°è ½ÇÀû ¹× ¼­ºñ½º/Á¦Ç° Æ÷Æ®Æú¸®¿À¸¦ È®´ëÇϱâ À§ÇØ M&A, ÆÄÆ®³Ê½Ê, ÇùÁ¤, Á¦ÈÞ, ¼­ºñ½º °³½Ã µîÀÇ Àü·«À» ÃßÁøÇϰí ÀÖ½À´Ï´Ù. PsychoGenics, Inc.´Â Ç¥ÇöÇü â¾àÀ» °­È­Çϱâ À§ÇÑ ¾à¸®³úÆÄ Ç÷§ÆûÀÎ eCubeÀÇ ¹ß¸Å¸¦ ¹ßÇ¥Çß½À´Ï´Ù. ÀüÀΰ£Çü ³ª³ë¹Ùµð ÀǾàǰÀ» °³¹ßÇÏ´Â ¡¸³ª³ë 100 ÇÁ·ÎÁ§Æ®¡¹¸¦ ¹ßÇ¥Çß½À´Ï´Ù. in vitro ¹× In Vivo Ç×ü ½ºÅ©¸®´× Ç÷§ÆûÀ» °áÇÕÇÑ ÀÌ ÅëÇÕ ±â¼úÀ» Ȱ¿ëÇÏ¿© ¹ÙÀÌ¿À½ÃÅä°ÕÀº ¿ÏÀü Àΰ£Çü ³ª³ë¹Ùµð ÀǾàǰÀÇ ±¤¹üÀ§ÇÑ °³¹ßÀ» ÃËÁøÇϴ ż¼¸¦ °®Ãß°í ÀÖ½À´Ï´Ù.

In Vivo CRO ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå In Vivo CRO ½ÃÀåÀÇ º¯¼ö, µ¿Çâ, ¹üÀ§

Á¦4Àå In Vivo CRO ½ÃÀå : ¸ð´Þ¸®Æ¼ ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦5Àå In Vivo CRO ½ÃÀå : ¸ðµ¨ À¯Çü ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦6Àå In Vivo CRO ½ÃÀå : ÀûÀÀÁõ ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦7Àå In Vivo CRO ½ÃÀå : GLP À¯Çü ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦8Àå In Vivo CRO ½ÃÀå : Áö¿ª ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦9Àå °æÀï ±¸µµ

Á¦10Àå ÁÖ¿ä ±Ç°í

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

In Vivo CRO Market Growth & Trends:

The global in vivo CRO market size is estimated to reach USD 7.96 billion by 2030, expanding at a CAGR of 8.13% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth of the pharmaceutical market in emerging countries, along with strong demand for numerous in vivo cell therapies, rapid advancements in material sciences, and complexities of drug-device combinations, has led to the demand for services in the region. Additionally, rising in vivo preclinical and clinical research, regulatory approval, expanding services by market players, and the burden of different diseases contribute to market earnings. Also, increasing outsourcing of preclinical and clinical services across developing economies at a lower cost is one of the major factors supporting the growth of in vivo CRO market.

Likewise, the increase in offshoring drugs to emerging economies has created immense demand for the market. Budget scrutiny in developed countries, pricing pressure, and changes in reimbursement schemes are some of the major factors anticipated to increase the adoption of cost-containment measures by drug sponsors in emerging countries such as India and China. Outsourcing development services such as preclinical in vivo services to contract service providers in emerging countries is expected to boost the demand for quality assurance & regulatory affairs services, thereby contributing to the rising demand for in vivo outsourced services. Stringent processes for FDA approval and regulatory changes in the EU region are expected to make the approval process in Europe complex. They are some of the major factors contributing to the offshoring of drug companies to emerging countries.

The COVID-19 pandemic has initially negatively impacted the clinical trials industry and the in vivo CRO market was no different! The shift in the focus of the biopharmaceutical industry on developing vaccines & therapies in response to COVID-19 has resulted in the unintended consequences of potentially disrupting clinical trials for other diseases. One of the key issues faced by companies operating in the cell and gene therapy industry is the untimely delivery of therapies to patients at required clinical sites. In addition, the administration of cell-based therapeutics poses several post-pandemic challenges. Hospitals have shown hesitation in offering cell therapy services owing to concerns over transmission of SARS-CoV-2, especially to vulnerable individuals. Patients have not been able to visit cell therapy centers either owing to the lockdowns or travel bans.

Furthermore, the key participants are engaged in strategies such as mergers & acquisitions, partnerships, agreements, collaborations, and service launches, among others, to expand their global footprints and service/product portfolio. For instance, in April 2023, PsychoGenics, Inc. announced the launch of eCube, a pharmaco-electroencephalography platform, to enhance phenotypic drug discovery. Similarly, in February 2023, Biocytogen recently introduced "the Nano 100 Project" to develop over 100 fully human nanobody drugs that target specific targets. This endeavor involves combining Biocytogen's proprietary RenNano, a mouse model capable of producing fully human nanobodies, with their advanced in vitro and in vivo antibody screening platforms. By leveraging these integrated technologies, Biocytogen is poised to facilitate the extensive development of fully human nanobody drugs.

In Vivo CRO Market Report Highlights:

Table of Contents

Chapter 1. Research Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. In Vivo CRO Market Variables, Trends & Scope

Chapter 4. In Vivo CRO Market: Modality Estimates & Trend Analysis

Chapter 5. In Vivo CRO Market: Model Type Estimates & Trend Analysis

Chapter 6. In Vivo CRO Market: Indication Estimates & Trend Analysis

Chapter 7. In Vivo CRO Market: GLP Type Estimates & Trend Analysis

Chapter 8. In Vivo CRO Market: Regional Estimates & Trend Analysis

Chapter 9. Competitive Landscape

Chapter 10 Key Recommendations

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â